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Abstract
Background: CXC chemokines are induced by inflammatory stimuli in epithelial cells and some, like MIG/CXCL9, IP–10/
CXCL10 and I–TAC/CXCL11, are antibacterial for Streptococcus pyogenes.
Methodology/Principal Findings: SpeB from S. pyogenes degrades a wide range of chemokines (i.e. IP10/CXCL10, I-TAC/
CXCL11, PF4/CXCL4, GROa/CXCL1, GROb/CXCL2, GROc/CXCL3, ENA78/CXCL5, GCP-2/CXCL6, NAP-2/CXCL7, SDF-1/CXCL12,
BCA-1/CXCL13, BRAK/CXCL14, SRPSOX/CXCL16, MIP-3a/CCL20, Lymphotactin/XCL1, and Fractalkine/CX3CL1), has no
activity on IL-8/CXCL8 and RANTES/CCL5, partly degrades SRPSOX/CXCL16 and MIP-3a/CCL20, and releases a 6 kDa CXCL9
fragment. CXCL10 and CXCL11 loose receptor activating and antibacterial activities, while the CXCL9 fragment does not
activate the receptor CXCR3 but retains its antibacterial activity.
Conclusions/Significance: SpeB destroys most of the signaling and antibacterial properties of chemokines expressed by an
inflamed epithelium. The exception is CXCL9 that preserves its antibacterial activity after hydrolysis, emphasizing its role as a
major antimicrobial on inflamed epithelium.
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Introduction
Streptococcus pyogenes is a strictly human pathogen that preferentially
colonizes the pharynx and the skin. Bacteria disseminating from the
primary site may cause life-threatening sepsis, necrotizing fasciitis,
and a toxic shock syndrome [1,2,3]. Despite the potential virulence
of S. pyogenes, many individuals are healthy carriers of the bacteria in
their upper airways, demonstrating that the bacteria can colonize
epithelial surfaces without eliciting an inflammatory response.
Extracellular enzymes from Streptococcus pyogenes have been
extensively studied and shown to be of importance for the
pathogenesis of this human pathogen. One of the most studied
enzymes is the streptococcal cysteine proteinase, SpeB. Several in
vitro, in vivo, and clinical studies have suggested a role for SpeB as an
important virulence factor [4,5,6,7,8]. The role for SpeB as
virulence factor in mouse models is not uncontroversial and there
havebeenreports using SpeB deletion mutants indicating that SpeB
is not a virulence factor [9,10]. SpeB has the ability to degrade the
human extracellular matrix protein fibronectin and vitronectin,
release inflammatory mediators such as interleukin 1b and
bradykinin from their precursors, cleave or degrade immunoglob-
ulins and complement factors, and also bind to the human cell
surface receptors integrins [11,12,13,14,15,16,17,18,19,20,21].
Dendritic cells, macrophages, and T-cells that reside in sub-
epithelial tissues recognize bacterial antigens, resulting in the
production of T-helper 1 polarized pro-inflammatory cytokines,
including IFN–c and TNF–a. These cytokines cause an inflamed
phenotype of epithelial cells, resulting in the production of host
defense molecules, including chemokines [22,23]. Chemokines are
divided into four groups, XC, CC, CXC, and CX3C chemokines,
depending on the presence of conserved NH2-terminal cysteine
residues [24]. MIG/CXCL9, IP–10/CXCL10 and I–TAC/
CXCL11 belong to the group of CXC chemokines [25,26,27].
They all share the ability to signal through CXC chemokine
receptor 3 (CXCR3), which is present on T cells and natural killer
cells. Ligand binding to the receptor results in the activation and
recruitment of these cells to sites of inflammation [28,29]. In
addition to the CXCR3 interactions, CXCL9, CXCL10, and
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Several other chemokines that are investigated in the present study
also possess direct antimicrobial activity (Table 1).
In a recent study, we showed that CXCL9, CXCL10, and
CXCL11 kill S. pyogenes, and that in particular CXCL9, is
produced at bactericidal concentration by inflamed pharyngeal
cells both in vivo and in vitro [31]. Furthermore, one of the major
surface proteins of S. pyogenes, the M protein, induces increased
production of MIG in IFN–c stimulated pharyngeal cells [32].
Proteolytic processing can significantly alter the signaling
activity of chemokines and is most likely one of the major
regulatory mechanisms for chemokines. The host proteases
gelatinase B/matrix metalloproteinase-9 (MMP-9) and neutrophil
collagenase/MMP-8 process several CXC chemokines including
CXCL9 and CXCL10 [33,34]. MMP-9 degrades CXCL10 and
cleaves CXCL9 at three different sites in its extended carboxy-
terminal region, while MMP-8 degrades CXCL9 and cleaves
CXCL10 at two positions [34]. It is currently not known how
proteolytic processing influences the antibacterial activity of
CXCL9, CXCL10, and CXCL11.
Corruption of innate immunity by bacterial proteases is a rapidly
growing field of research (for a recent comprehensive review see
[35]), and processing of chemokines by bacterial proteases has
recently gained substantial attention. Metalloproteases from
Pseudomonas aeruginosa degrade several chemokines [36]. Further-
more, an elastase from this bacterium degrades the chemokine-like
antimicrobial peptide LL-37 [37]. In the same study by
Schmidtchen et al. SpeB from S. pyogenes was also shown to degrade
LL-37,which is of particular interestfor the present study. S. pyogenes
has recently been shown to produce another interesting protease,
the cell wall-anchored serine protease, SpyCEP, that degrades the
CXC chemokine, IL-8/CXCL8, and thus promotes resistance
against of neutrophil killing [38,39,40,41]. SpyCEP was very
recently also shown to degrade two additional CXC chemokines,
GCP-2/CXCL6 and GROa/CXCL1 resulting in impaired
neutrophil recruitment [42]. These findings, together with previous
observations concerning direct and indirect enzymatic activities on
host immune factors, highlight S. pyogenes as one of the most versatile
modulators of innate and adaptive immune responses.
Results
SpeB degrades or cleaves most human chemokines, but
not CXCL8 and CCL5
Since it has been shown that the streptococcal cysteine
proteinase SpeB can cleave and inactivate the antimicrobial
peptide LL-37 [37], we hypothesized that SpeB also could degrade
or process chemokines that share many properties with antimi-
crobial peptides. We therefore incubated 2 mg of the human
chemokines CXCL9, CXCL10, CXCL11, CXCL4, CXCL8,
CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7,
CXCL12, CXCL13, CXCL14, CXCL16, CCL5, CCL20,
CCL28, XCL1, and CX3CL1 with a small amount of SpeB
(pmol range) for 2 hours. When the samples were analyzed by
SDS-PAGE, this revealed that SpeB partially or completely
degrades most of these chemokines (Fig. 1A). However, CCL5 and
CXCL8 were completely resistant to cleavage by SpeB, and
CXCL16 and CCL20 were only partly degraded. It should be
added for clarity that both intact and fragmented chemokines
sometimes appear as multiple bands due to oligomerization, and
that CXCL9 migrates on SDS-PAGE as an apparently larger
molecule than its actual mass.
What was most interesting in relation S. pyogenes is that there
were differential SpeB activities on the closely related ELR-
Table 1. Known antimicrobial activities of the chemokines used in the present study.
Chemokine Activity Reference(s)
CXCL1/GRO-a E. coli, S. aureus, S. typhimurium, C. albicans [59,60]
CXCL2/GRO-b E. coli, S. aureus [59]
CXCL3/GRO-c E. coli, S. aureus [59]
CXCL4/PF4 S. typhimurium [60,61]
CXCL5/ENA-78 S. pyogenes [62]
CXCL6/GCP-2 S. pyogenes, E. coli, P. aeruginosa, S. dysgalactiae, S. aureus, N. gonorrhoeae, E. faecalis /
No activity on E. coli, S. aureus
[62,63]/[59]
CXCL7/NAP-2 S. pyogenes [62]
CXCL8/IL-8 S. aureus, S. typhimurium, C. albicans [60]
CXCL9/MIG E. coli, S. aureus, S. pyogenes, N. gonorrhoeae [31,59,64]
CXCL10/IP10 E. coli, S. aureus, S. pyogenes [31,59]
CXCL11/I-TAC E. coli, S. aureus, S. pyogenes [31,59]
CXCL12/SDF-1a E. coli, S. aureus [59]
CXCL13/BCA-1 E. coli, S. aureus [59]
CXCL14/BRAK E. coli, S. aureus [59]
CXCL16/SRPSOX N/D -
CCL5/RANTES No activity on E. coli, S. aureus / S. aureus, S. typhimurium, C. albicans [59] / [60]
CCL20/MIP-3a E. coli, S. aureus [59]
CCL28/MEC E. coli, S. aureus, S. pyogenes, S. mutans, K. pneumoniae, P. aeruginosa, C. albicans [65]
XCL1/Lymphotactin E. coli, S. aureus, S. typhimurium, C. albicans [59,60]
CX3CL/Fractalkine No activity on E. coli, S. aureus [59]
doi:10.1371/journal.pone.0004769.t001
SpeB Degrades Chemokines
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where CXCL9 was processed to a smaller fragment rather than
being degraded, CXCL10 was almost completely degraded, and
CXCL11 was completely degraded. Furthermore, SpeB processes
CXCL9 at lower concentrations and the generated fragment is
resistant to further degradation even after prolonged incubation or
higher concentrations of SpeB (Fig. 1B and data not shown). It
should be noted that in all SDS-PAGE separations except in
Fig. 1B, we utilized an SDS-PAGE loading buffer containing
dithiothreitol (DTT) and iodacetamide to disrupt oligomers of
chemokines. In the experiments shown in Fig. 1B we used
standard SDS-PAGE loading buffer only containing b-mercapto-
ethanol as a reducing agent. This allows for the visualization of
oligomers, and therefore our interpretation of Fig. 1B is that SpeB
either aids in the disruption of CXCL9 oligomers, or has direct
proteolytic activity on both monomers and oligomers of CXCL9.
Furthermore, CXCL9 was partly processed to fragments,
comparable to what could be seen with purified SpeB, after
incubation with sterile filtered culture supernatant from wild type
AP1 bacteria, while supernatant from the isogenic SpeB negative
strain did not hydrolyze CXCL9 (Fig 1C). This indicates that
under these conditions there is no other secreted factor than SpeB
from S. pyogenes that can degrade CXCL9.
The three CXC chemokines CXCL9, 10, and 11 are closely
related, act through the same receptor (CXCR3), are expressed in
the context of streptococcal pharyngitis, are antibacterial towards
S. pyogenes [31], and are induced by the cell wall-anchored M
protein from S. pyogenes [32]. We therefore decided to further
elucidate the receptor activating and antimicrobial activity of
CXCL9, CXCL10, and CXCL11 after SpeB hydrolysis.
Figure 1. SpeB degrades or processes several human chemokines. Panel A: The streptococcal cysteine proteinase was incubated with
human recombinant chemokines and separated on 16.5% Tris-Tricine SDS-PAGE. Chemokines (standardized ligand and common name) are indicated
above the panels and presence or absence of SpeB during incubation is indicated with minus or plus signs below the panels. Panel B: Recombinant
MIG/CXCL9 was incubated with 1, 0.1, or 1 pmol of active SpeB and separated on 16.5% Tris-Tricine SDS-PAGE. CXCL9 incubated with buffer alone is
shown to the left. Panel C: Two micrograms of recombinant human CXCL9 was incubated with dilutions (as indicated) of sterile filtered culture
supernatants from wild type S. pyogenes AP1 and SpeB-negative isogenic derivative AL1 and separated on 16.5% Tris-Tricine SDS-PAGE. CXCL9
incubated with buffer alone is shown to the left.
doi:10.1371/journal.pone.0004769.g001
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antibacterial after SpeB hydrolysis
In particular CXCL9, and to some degree CXCL10, CXCL11,
seem to be important for the antibacterial activity against S.
pyogenes on inflamed respiratory tract epithelium [31]. We
therefore investigated how SpeB cleavage affected the antimicro-
bial activity of these three chemokines on S. pyogenes strain AP1 of
the important M1 serotype. A viable count assay revealed that, not
surprisingly, the completely degraded CXCL11 and the nearly
completely degraded CXCL10 had very low or no killing activity
towards S. pyogenes AP1 bacteria, while the corresponding intact
CXCL10 and CXCL11 very efficiently killed the bacteria (Fig. 2B,
CXCL10 and CXCL116SpeB). This was also confirmed by
transmission electron microscopy (TEM) of bacteria incubated
with intact and SpeB-treated CXCL10 and CXCL11, where both
CXCL10 and CXCL11 caused membrane disruption and
disintegration of bacterial chains while SpeB-treated CXCL1010
and CXCL11 had no visible effect on that bacteria when
compared to bacteria incubated with buffer alone (Fig. 2B,
Control, CXCL10 and CXCL11, Buffer / SpeB). In contrast to
the findings for CXCL10 and CXCL11, there was no significant
difference in killing of AP1 bacteria between SpeB-treated and
intact CXCL9 (Fig. 2A, CXCL96SpeB). This was also confirmed
by TEM where CXCL9 irrespective of SpeB-treatment caused
membrane disruption and disintegration of bacterial chains
(Fig 2B, CXCL9, Buffer / SpeB).
Taken together, these experiments indicate that SpeB destroys
the antibacterial activity of CXCL10 and CXCL11, while SpeB-
processing of CXCL9 with loss of nearly half of the molecule does
not influence the potent antibacterial activity of CXCL9 against S.
pyogenes.
SpeB-cleaved CXCL9 does not signal through CXCR3
Since the SpeB-generated CXCL9 fragment had retained
antibacterial activity, we decided to examine if the receptor
activating properties were affected. In order to do this, we
incubated CXCL9 under reducing conditions (DTT) with or
without SpeB. To minimize the proteolytic activity SpeB might
have on cells, we terminated the reactions using the specific
cysteine proteinase inhibitor E-64 [43]. These samples were
analyzed by Tris-Tricine SDS-PAGE revealing that DTT and E-
64 treated CXCL migrated as an apparently slightly smaller
protein than untreated CXCL9 (Fig. 3A, lanes A and C). This
could possibly be explained by some minor spontaneous hydrolysis
of CXCL9. In contrast, addition of SpeB to the reaction led to a
complete conversion of CXCL9 into a fragment with an apparent
mass of approx. 10 kDa (Fig. 3A, lane B). Intact and SpeB-treated
CXCL9 was then investigated for receptor interaction by
measuring their effects on intracellular calcium levels in
CXCR3-transfected pre-B cells. The results show that SpeB-
processed CXCL9 had lost all the receptor-stimulating capacity of
intact CXCL9.
Identification and purification of the SpeB-generated
fragment of CXCL9
The finding that SpeB-processed CXCL9 had retained
antibacterial activity but lost its receptor stimulating activity was
somewhat surprising. We therefore attempted to identify the SpeB-
generated fragment of CXCL9 by mass spectrometry, after several
failed attempts to obtain an NH2-terminal sequence by Edman
degradation. CXCL9 was digested with SpeB as described above
for the receptor activating experiments and analyzed using
MALDI-TOF MS and matching against theoretical fragments of
the known CXCL9 holopeptide. These experiments demonstrated
two major CXCL9 cleavage products of 6,290.482 and 6,306.314
Dalton respectively (Fig. 4A). The Expasy FindPept tool analysis
revealed that this corresponds to a peptide from CXCL9 spanning
Figure 2. The effect of SpeB on the antibacterial activity of
0.5 mM CXCL9, CXCL1010, and CXCL11. Panel A: CXCL9, CXCL10,
and CXCL11 incubated with SpeB were compared to the intact
molecules for killing of S. pyogenes strain AP1. Bars represent mean
bacterial killing in percent with standard deviation determined from at
least three independent experiments. Panel B: Transmission electron
micrographs of AP1 bacteria incubated with intact (CXCL9-11, Buffer) or
SpeB treated (CXCL9-11, SpeB) CXCL9, CXCL10, and CXCL11. Control
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Furthermore, the additional peak most likely represents the mass
of the same peptide but with an oxidized tryptophan (Fig. 4B, W),
strengthening the identification of the peptide within CXCL9.
This suggests, that the proteolytic activity of SpeB on CXCL9
occurs both in the amino-terminal and carboxy-terminal part of
the molecule, generating a fragment spanning the amino acids 18
to 73 of the CXCL9 holopeptide.
In order to confirm the antibacterial activity of the SpeB
generated CXCL9 fragment, a peptide spanning amino acids 18
to 73 of CXCL9 was synthesized. This peptide had no receptor
stimulating activity that was expected, but somewhat surprising the
antibacterial activity was also very low (data not shown). This
could be interpreted as a misidentification of the fragment or that
the synthetic peptide did not have its functionally correct
conformation. In order to elucidate this, we purified SpeB-
processed CXCL9 using anion exchange chromatography. This
approach is based on the fact that minor remaining fragments,
especially from the carboxy-terminal end of CXCL9 are highly
positively charged and would, under the conditions used, be
filtrated through the column, while the 18–73 fragment with a
lower pI will interact with the matrix (See Table 2). Using this
method we could purify the SpeB generated CXCL9 fragment to
homogeneity (Fig. 5, inset). This purified fragment was subse-
quently tested for antibacterial activity against S. pyogenes using the
viable count assay as described above. This revealed that SpeB-
generated MIG 18–73 has an antibacterial activity against S.
pyogenes comparable to intact CXCL9 (Fig. 5).
Homology modeling of the SpeB generated CXCL9
fragment
It was somewhat surprising that CXCL9 was much more
resistant to SpeB compared to the closely related molecules
CXCL10 and CXCL11. When aligning the amino acid sequences
of SpeB-processed CXCL9 with CXCL10 and CXCL11, there
are no obvious explanations for this phenomenon except minor
stretches of divergent sequence (Fig. 6A). Therefore, we generated
a structure homology model of SpeB-processed CXCL9 using the
recently developed M4T method [44] with a variant form of
CXCL5 [45] as template. This model was compared to the known
structures of CXCL10 and CXCL11 [46,47]. This revealed that
Figure 3. SpeB-hydrolyzed CXCL9 does not signal through
CXCR3. Panel A: CXCL9 was incubated with SpeB / DTT or DTT and
terminated by addition of the cysteine proteinase inhibitor E-64.
Samples were separate on 16.5% SDS-PAGE and compared with intact
CXCL9. Panel B: Analysis of calcium flux in Fura-2 loaded CXCR3-
expressing pre-B cells upon stimulation with MIG incubated with SpeB /
DTT or CXCL9 incubated with DTT alone, both terminated with E-64.
Peak values of the Ex340/380 ratio fluorescence curves are presented as
means and standard deviations from three independent experiments.
doi:10.1371/journal.pone.0004769.g003
Figure 4. CXCL9 is trimmed amino-terminally and carboxy-
terminally by SpeB. Panel A: SpeB-processed CXCL9 was analyzed by
MALDI-TOF mass spectroscopy. Masses in Dalton are indicated above
the to main intensity peaks. Panel B: The primary sequence of mature
CXCL9 with the proposed SpeB-generated fragment constituting amino
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and CXCL11 with three amino-terminal antiparallel b-sheets and a
carboxy-terminal a-helix (Fig. 6B). Some of the differences that can
be noted is that CXCL11 has a somewhat less compact structure
compared to both CXCL9 and CXCL10 with several internal
flexible loops, and that CXCL has an additional internal predicted
310-helix between the b-sheets and the carboxy-terminal a-helix.
Discussion
For the first time we show that the cysteine proteinase SpeB
from the important human pathogen S. pyogenes has differential
proteolytic activity on human chemokines. Most chemokines are
completely degraded, while a few are partly or completely resistant
to the proteolytic activity of SpeB. The differential activity seen on
the closely related ELR-negative CXC chemokines CXCL9,
CXCL10, and CXCL11 was particularly interesting, since these
chemokines are highly expressed by inflamed pharyngeal epithe-
lium and have strong antibacterial activity against S. pyogenes [31].
More detailed analysis of these chemokines revealed that CXCL10
and CXCL11 were completely degraded by SpeB, resulting in loss
of antibacterial activity and consequently also receptor stimulating
activity. In contrast, CXCL9 has a SpeB-resistant core spanning
amino acids 18–73 that has no receptor stimulating activity but
with retained antibacterial activity against S. pyogenes. The finding
that such a fragment of CXCL9 has no CXR3-stimulating activity
is in concordance with previous findings that CXCL9 1–74 and
74–103 have low or no chemotactic activities [48], and further
establishes that both the carboxy-terminal and amino-terminal
parts of MIG are important for activation of the receptor. Our
previous finding that the synthetic peptide CXCL9 57–83 has a
strong antibacterial against S. pyogenes [31] could appear as being in
conflict with our present finding that synthetic CXCL9 18–73 is
not antibacterial and thereby indicate a misidentification of the
SpeB generated fragment. In addition to what we consider
unambiguous mass spectroscopy identification, CXCL9 57–83 is
derived from the putative amphiphatic a-helix containing a
classical sequence of antibacterial amino acids. CXCL9 18–73 on
the other hand is derived from the NH2-terminal region of the
holopeptide, and only contains some of the COOH-terminal
antibacterial motifs. Native CXCL9 (and recombinant) is held
together by two disulphide bonds corresponding to what in
CXCL8 and CXCL10 have been shown to be crucial for
oligomerization. The peptide CXCL9 18–73 is synthesized as a
linear peptide and it is very unlikely that it can adopt a structure
that allows the naturally occurring oligomerization. We hypoth-
esize that CXCL9 18–73 fragments generated by SpeB oligomer-
ize and thereby expose their antibacterial motifs in combination,
enhancing the antibacterial activity.
The structural differences between the homology model of
CXCL9 18–73 on one hand, and CXCL10 and CXCL11 on the
other hand, might partly explain the SpeB resistance of this part of
CXCL9; since SpeB is known to preferentially cleave extended
loops [49]. Nevertheless, most of the explanation probably lies
within the part of CXCL9 that is not in the model; the amino-
terminal and carboxy-terminal degraded by SpeB cannot be
modeled, indicating that these parts are largely unstructured or
flexible. This is also supported by the fact that there currently is no
experimentally determined structure of CXCL9. These potentially
unstructured or flexible parts of CXCL9 might serve as ‘‘bait’’ for
SpeB and other proteases to divert the activity from the
antibacterial core of the molecule. From an evolutionary point
of view, it is interesting that CXCL9 seems to have evolved
towards a robust antibacterial chemokine with relatively weak
receptor interaction, while CXCL10 and CXCL11 both have
more efficient interaction with the receptor but are less
antibacterial and more protease sensitive than CXCL9. What is
very surprising is that the highly antibacterial 18–73 fragment of
CXCL9 has a predicted structure that is very similar to CXCL10
and CXCL11, but is not as highly positively charged as these
molecules (Fig 6B and Table 2). This might indicate that the












CXCL10 8645.4 11.22 31 23 17 6
CXCL11 8306.10 10.34 30 20 17 6
CXCL9 11723.38 10.59 29 38 29 7
CXCL9 18–73 6292.66 8.39 22 18 9 7
doi:10.1371/journal.pone.0004769.t002
Figure 5. Dose dependent killing of S. pyogenes killing by
CXCL9 and the SpeB generated fragment. The purified 18–73
SpeB generated CXCL9 fragment was compared to the intact CXCL9 for
killing of S. pyogenes strain AP1. Curves represent mean bacterial killing
in percent with standard error determined from at least three
independent experiments. Inset: Intact CXCL9 and ion exchange




PLoS ONE | www.plosone.org 6 March 2009 | Volume 4 | Issue 3 | e4769overall structure of an chemokine is more important for
antibacterial activity than overall charge, at least against S. pyogenes
and possibly other related Gram-positive bacteria.
Taken together, or results indicate that SpeB has the capacity to
destroy most of the signaling properties of chemokines expressed
by an inflamed epithelium by degradation of CXCL10, CXCL11,
and removing the signaling activity of CXCL9 through CXCR3.
CXCL9 on the other hand seems to have evolved to resist the
SpeB activity and to preserve its antibacterial activity towards S.
pyogenes. In the context of a bacterial infection with release of
several chemokines, other antimicrobial compounds, and impor-
tantly other bacterial proteins the situation is very complex and
cannot be reduced to a single interaction between a protease and a
substrate. For instance, the streptococcal inhibitor of complement
(Sic) can probably inhibit the antibacterial activity of the SpeB
generated CXCL9 fragment since it is known to inhibit intact
CXCL9-11 [31]. Furthermore, the cell wall-anchored serine
proteinase SpyCEP, most likely contributes to inhibition of pro-
inflammatory and antibacterial activities of chemokines during
infection [38,39,40,41,50]. Nevertheless, we believe that our
results deepen the understanding of innate immunity control of
S. pyogenes and emphasize the role for CXCL9 as one of the major
antimicrobial compounds on inflamed airway epithelium.
Materials and Methods
Chemicals, bacterial strains and proteins
Recombinant human chemokines were purchased from Pepro-
tech (London, UK). All other chemicals were purchased from
Sigma (St Louis, MO) if not noted otherwise. The S. pyogenes strain
AP1 (40/58) of serotype M1 from the WHO Collaborating Center
for Reference and Research on Streptococci, Prague, Czech
Republic. The S. pyogenes strain AL1 is an isogenic derivative of
strain AP1 lacking active SpeB production generated as previously
described [19,51]. For maximal SpeB production, S. pyogenes was
cultured in C-medium (CM) consisting of 0.5% (w/v) Proteose
Peptone No. 2 (Difco, Detroit, MI) and 1.5% (w/v) yeast extract
(Oxoid, Basingstoke, England) dissolved in CM buffer (10 mM
K2PO4, 0.4 mM MgSO4, and 17 mM NaCl pH 7.5) [52]. When
culturing strain AL1, CM was supplemented with 150 mg / ml of
kanamycin. SpeB was purified from the culture supernatant of
AP1 cultured in CM using ion exchange chromatography as
previously described [53]. Activity of SpeB was determined by
active site titration using the specific cysteine proteinase inhibitor
L-trans-epoxysuccinylleucylamido(4-guanidino)butane (E-64) [43]
as previously described [54]. Throughout the paper, the amount of
SpeB is described as pmol active enzyme.
Incubation of chemokines with SpeB or culture medium
Two mg each of recombinant chemokines CXCL9, CXCL10,
ICXCL11,CXCL4, CXCL8,CXCL1, CXCL2, CXCL3,CXCL5,
CXCL6, CXCL7, CXCL12, CXCL13, CXCL14, CXCL16,
CCL5, CCL20, CCL28, XCL1, and CX3CL1 were incubated
with 1 pmol SpeB in PBS supplemented with 10 mM dithiothreitol
(DTT) for 2 h at 37uC. Two mg of recombinant CXCL9 was
incubated for 2 h at 37uC with 5, 0.5, or 0.05 mlo f0 . 2mm-filtered
culture medium from AP1 or AL1 in PBS supplemented with
10 mM DTT. Samples were analyzed on 16.5% Tris-Tricine SDS-
PAGE and stained with Commassie Brilliant Blue.
Viable count assay
AP1 bacteria were cultured to mid-exponential growth phase in
Todd-Hewitt Broth (TH) (Becton Dickinson, Sparks, MD),
washed, and diluted in 10 mM Tris-HCl (pH 7.5) with 5 mM
Figure 6. Sequence and structural comparison of CXCL10, CXCL11, and SpeB-processed CXCL9. Panel A: ClustalW alignment of the
SpeB-generated fragment of CXCL9 (18–73) with mature CXCL10 and CXCL11. Amino acid identities are shown in dark grey, similarities in light grey,
and consensus sequence is shown under the alignment. Panel B, visualization of the known structures of mature CXCL10 and CXCL11, and homology
model of the SpeB-generated CXCL9 fragment (18–73) using a CXCL7 -variant as the template. H-strands are shown in yellow, Æ-helices in purple, 310-
helices in blue, and loops in turquoise.
doi:10.1371/journal.pone.0004769.g006
SpeB Degrades Chemokines
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6 colony forming units (CFU) /
mL) were incubated together with chemokines, at various
concentrations or buffer alone for 2 h at 37uC. To quantitate
bactericidal activity, serial dilutions of the incubation mixtures
were plated on agar-solidified TH and the number of CFUs were
determined after an overnight incubation at 37uC.
CXCL9/SpeB incubation, CXCR3 transfectants, and
calcium flux experiments
10 mg of CXCL9 was incubated with 5 pmol SpeB in 20 mlP B S
supplemented with 10 mM DTT or in PBS/DTT alone for 2 h at
37uC. Reactions were terminated by addition of E-64 to a final
concentration of 20 mM. Samples were analyzed on 16.5% Tris-
Tricine SDS-PAGE. Stable transfectants of the pre-B cell line 300-
19 expressing CXCR3 [28], were used to assay for receptor
dependent responsiveness to CXCL9 and SpeB-processed CXCL9,
respectively. Fura-2 loaded transfectants were stimulated using
100 nM intact CXCL9, CXCL9 incubated with SpeB / DTT / E-
64 as described above, or SpeB / DTT / E-64. The [Ca
2+]i -related
fluorescence changes were recorded as described [28,55,56].
Negative staining and transmission electron microscopy
Bacteria were incubated for 2 h at 37uC in incubation buffer with
the chemokines placed ona carbon coated copper grid and negatively
stained as described by Engel and Furthmayr [21]. The samples were
washed twice with water and stained on two drops 0.75% uranyl
formate. Samples were observed using a Jeol JEM 1230 transmission
electron microscope operated at 60 kV accelerating voltage, and
recorded with a Gatan Multiscan 791 CCD camera.
Statistical analysis
Statistical significance was determined based on the Student’s t-
test for paired observations.
Determination of the CXCL9 cleavage sites by MALDI-
TOF Mass Spectrometry (MS)
The CXCL9/SpeB reactions, terminated with E-64 as
described above, were desalted and concentrated using C18
Ziptips (Millipore, Bedford, MA) according to the manufacturer’s
instructions. Briefly, the micro-columns were washed with 0.1%
TFA and eluted with 1 ml 50–90% acetonitrile in 0.1% TFA
directly onto MALDI Anchorchip target plates pre-spotted with
1 ml of 1 mg/ml sinnapinic acid (SA) in 90% acetonitrile / 0.1%
TFA. The MALDI target plate was loaded into a Bruker Reflex III
MALDI-TOF mass spectrometer (Bruker Daltonic GmbH, Bre-
men, Germany). The polarity of the instrument was set for positive
ions with a delayed extraction and the detector for reflector mode.
The acceleration voltage was 20 kV and 50–75 shots per sample
were summed in each spectrum for an improved signal-to-noise
ratio. Spectra were calibrated using insulin and myoglobin
standards diluted to 1–2 mM and applied as above in 1 mlo f
90% acetonitrile/0.1% TFA. Evaluated machine-specific proto-
cols and settings for the mass spectrometer were used for each of
the calibrants. The EXPASY server FindPept tool (http://www.
expasy.ch) was used to search for experimentally obtained peptide
masses matching with the CXCL9 sequence considering mass
values as well as post-translational / experimental modifications of
CXCL9. Tolerance was set to 0.5 Daltons, cysteines in reduced
form and methionines as well as tryptophans as oxidized.
Purification of the SpeB-generated CXCL9 fragment
For ion exchange purification of the SpeB generated CXCL9
fragments 200 mg of SpeB was incubated with 40 pmol SpeB and
10 mM DTT in 400 ml of PBS. The sample was applied to a
HiTrap SP HP column (GE Healthcare, Uppsala, Sweden) using
an A ¨kta Prime (GE Healthcare) liquid chromatography system.
The column was washed with 5 column volumes of 50 mM
HEPES (pH 7.5) and proteins were eluted using a linear gradient
over 25 column volumes reaching 1 M NaCl. The fractions were
analyzed on SDS-PAGE and relevant fractions were pooled and
concentrated using a Centricon YM 3000 (Millipore).
Homology modeling and structural comparisons
A homology model of the SpeB-processed form of CXCL9 was
generated using Multiple Mapping Method with Multiple
Templates (M4T) (http://www.fiserlab.org/servers/m4t) [44]
using a NAP-2/CXCL7 variant (PDB 1TVX) [45] as a template.
The CXCL9 model and the previously determined structures of
CXCL10 (PDB 1LV9) [46] and CXCL11 (PDB 1RJT) [47] were
visualized using VMD 1.8.6 (http://www.ks.uiuc.edu/Research/
vmd/) [57] and high-resolution images were generated using the
Tachyon ray tracer [58].
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